STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA https://lnkd.in/g5cGHSDH ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Pennsylvania NY NJ Biotech Networks
Biotechnology
Life science news & jobs from Pennsylvania, New York & New Jersey, including Philadelphia & NYC. A Biotech Networks hub.
About us
Life science news, jobs and events from Pennsylvania, New York and New Jersey, including Philadelphia & NYC. Part of Biotech Networks, connecting #biotech since 2008.
- Website
-
https://pnbn.org
External link for Pennsylvania NY NJ Biotech Networks
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Founded
- 2022
Updates
-
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach https://lnkd.in/gCUHDEJ3 In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard oncology endpoint—in their first-line non-small cell lung [...]
-
ASCO: Pfizer one-ups J&J with Talzenna combo’s broad castration-sensitive prostate cancer win https://lnkd.in/ey5HJK65 After winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sensitive patient population compared with J&J’s [...]
-
ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger | Fierce Life Sciences https://lnkd.in/gRh9Ymfc Eli Lilly took to the stage at the American Society of Clinical Oncology meeting in Chicago to share early data for a new drug candidate that could, if all goes right, challenge the dominance of [...]
-
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer https://lnkd.in/gEaWFPCs You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest… Click here to view original [...]
-
Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration https://lnkd.in/gJXBU-zN Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, through a collaboration that could generate up to $10.5 billion [...]
-
Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation | Fierce Life Sciences https://lnkd.in/gF5ajdJ6 Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s fast early development system. Click here to [...]
-
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage https://lnkd.in/gVdpRdPy TREMFYA® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis HORSHAM, Pa., May 28, 2026 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration [...]
-
Braeburn Presents New Data at 2026 ASCP Annual Meeting Demonstrating Opioid Withdrawal Suppression at Low Buprenorphine Plasma Concentrations https://lnkd.in/gcwfikch PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ — Braeburn Inc. today announced the presentation of three posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, FL, adding to the growing body [...]
-
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi https://lnkd.in/ghzeAhah AstraZeneca has fired another shot in its bladder cancer competition with Merck’s Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients [...]